SYRE

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Sloan SheldonChief Medical Officer --8.3k shares SellJun 3, 2026 $625.0K8.3k shares $75.00 $72.51
Sloan SheldonChief Medical Officer --8.3k shares Grant / ExerciseJun 3, 2026 $228.8K8.3k shares $27.46 $72.51
Turtle CameronDirector, Officer: Chief Executive Officer --8.1k shares SellJun 1, 2026 $574.5K8.1k shares $70.50 $72.51
Turtle CameronDirector, Officer: Chief Executive Officer --3.6k shares SellJun 1, 2026 $246.9K3.6k shares $69.40 $72.51
Turtle CameronDirector, Officer: Chief Executive Officer --3.3k shares SellJun 1, 2026 $235.1K3.3k shares $71.38 $72.51
Burrows Scott LChief Financial Officer --3.1k shares SellJun 1, 2026 $223.4K3.1k shares $72.06 $72.51

News

globenewswire.comSpyre Therapeutics Announces Grants of Inducement Awardsglobenewswire.comJun 5

zacks.comSYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Upzacks.comJun 4

globenewswire.comSpyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpAglobenewswire.comJun 3

globenewswire.comSpyre Therapeutics to Participate in Upcoming June Investor Conferencesglobenewswire.comMay 26

Trade SYRE

About Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

CEO: Cameron Turtle
IPO Date: Apr 7, 2016

Market Data

Open: $77.77
High: $78.90
Low: $73.06
Volume: 1.5M
52W High: $78.90
52W Low: $13.93

Valuation

Market Cap: $4.4B
Enterprise Value: $4.4B

Financials

Free Cash Flow: $-169M
Revenue: $0
Net Income: $-155M
Cash: $86M
Debt: $0

Events

EarningsAug 4

EPS est. -0.73